Project Description

Cage Bio
The Body’s Largest Organ Needs The Care

Date & Time:

October 12, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Skin is the body’s largest organ so it makes sense that skin conditions represent the largest single category of human diseases. Currently patients with skin diseases such as Atopic Dermatitis (eczema), Rosacea, Alopecia (hair loss), and Vitiligo spend upwards of $13B a year for systemic treatments with varying degrees of efficacy and significant side effects.

CAGE Bio believes that systemic exposure to drugs should be an exception and the company has developed an Ionic Liquid (IL) platform that allows medication to be applied topically to the area of need, delivering it across the outer layer of the skin. This enables the company to engineer diverse Ionic Liquids tailor-made for multiple therapeutic areas.

CAGE Bio has a robust pipeline of Ionic Liquid formulations and have begun to enroll patients in Phase 2 trials of the Rosacea program after a very successful Phase 1.

Join our webinar to hear from CAGE Bio CEO, Nitin Joshi as he discusses the opportunity this breakthrough technology presents.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.